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Medical Therapy for Intermittent Claudication
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Medical therapy to improve symptoms, stabilise the underlying vascular disease and improve lower limb outcomes is an
important and effective adjunct to lifestyle modification and surgical or endovascular interventions in patients with IC.
Randomised placebo controlled trials have shown that the phosphodiesterase III inhibitor cilostazol 100 mg bid improves
pain-free and maximum walking distance, as well as quality of life, in a range of patients with intermittent claudication
in whom there is no evidence of tissue necrosis or rest pain. This review summarises the evidence from 8 pivotal trials of
cilostazol involving over 2000 patients with intermittent claudication treated for up to 6 months. There is comparatively
less evidence to support the use of other treatment modalities for relief of symptoms in intermittent claudication, but there
is considerable interest in therapeutic angiogenesis to promote new vessel formation and enhance collateralisation of the
lower limb using recombinant growth factor proteins or gene transfer strategies. The rationale for therapeutic angiogenesis
is discussed, together with the most recent results from randomised trials in patients with peripheral arterial disease.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Keywords: Intermittent claudication; Cilostazol; Angiogenesis; Exercise tolerance; Medical therapy.Introduction
The age-adjusted prevalence of atherosclerotic peri-
pheral arterial disease (PAD) is approximately 12%,
of which intermittent claudication (IC) is the most
common symptom.1 IC is painful, disabling and infre-
quently requires surgical intervention, but patients
complain of significant mobility and lifestyle restric-
tions which affect their quality of life (QOL). In the
Edinburgh Artery Study, 4.5% of all men and women
aged 55e74 years had IC.2 Thus, the clinical and prog-
nostic significance of PAD, especially IC, should not
be under-estimated. A diagnosis of PAD invariably
means that significant occlusive arterial disease (silent
or symptomatic) is present in other parts of the circu-
lation.3 For example, up to two-thirds of patients with
PAD have significant coronary artery disease (CAD)
and 30e50% will have evidence of prior stroke on
brain imaging.4 Not surprisingly, therefore, the
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pressure index (ABPI), correlates with reduced
survival.5
Less than 10% of patients with IC require surgical
or endovascular intervention, but they all require
medical therapy (including pharmacological and
non-pharmacological interventions) to improve
symptoms, exercise tolerance and clinical outcomes
(i.e reduced progression to critical limb ischaemia
and improved patient survival). There are a number
of drug therapies used to provide immediate relief
of symptoms in IC,6 as well as treatments aimed at
modifying the disease process in order to achieve ath-
erosclerotic plaque stabilisation and regression (and
indirectly improve lower limb blood flow and symp-
toms in the longer term).6,7
Pharmacological Therapies to Improve
Symptoms in IC
Assessing the efficacy of drugs used for relief of IC
(especially older drugs that were licensed prior to
the international standardisation of clinical trial re-
quirements for marketing approval) has been fraughtlar Surgery. Published by Elsevier Ltd. All rights reserved.
315Medical Therapy for Intermittent Claudicationwith difficulty, mainly because of poor study design,
variety of endpoints, often a lack of double-blind
placebo comparison and a degree of selection bias in
publication. This was highlighted very clearly by
Cameron et al. almost 20 years ago, focusing in particu-
lar onnaftidrofuryl.8 Bymodern expectations, naftidro-
furyl lacks clinical trials of sufficient size and duration
to adequately and consistently demonstrate clinical
and cost-effectiveness,9 but it is still included (perhaps
controversially) as a treatment option in the latest iter-
ation of the Scottish IntercollegiateGuidelinesNetwork
(SIGN) recommendations for PAD.10
There is some evidence that the antiplatelet agent
ticlopidine11 and gingko biloba special extract (Egb
761)12,13 significantly improve pain-free walking dis-
tance in patients with IC, but numerous other agents,
e.g pentoxifylline, garlic, testosterone, levocarnitine,
propionyl-L-carnitine and chelation therapy, have
been evaluated in randomised controlled trials which
showed lack of consistent and/or clinicallyworthwhile
efficacy.6,14e17
Clinical trial design and regulatory requirements
The European Medicines Evaluation Agency has de-
fined certain criteria for the design of (phase III) clin-
ical trials to evaluate and register new treatments for
IC. In particular, the primary endpoints must be based
on standardised treadmill exercise tests to define
pain-free and maximal walking distances; patients in-
cluded in the trial must demonstrate repeatable symp-
toms and walking limitation on the treadmill at
baseline, prior to randomisation; and the absolute
claudication distance at baseline should be in the re-
gion of 100e300 m. Treadmill exercise tests are notori-
ously associated with wide intra- and inter-individual
variability, there is a significant placebo effect and
new guidelines exclude patients who might have
other exercise-limiting symptoms as well as IC. Simi-
lar treadmill testing has been used to demonstrate the
efficacy of antianginal drugs, but in ischaemic heart
disease exercise-induced ECG changes (ST-segment
depression) are more reproducible than symptoms.
Unfortunately, in IC the evaluation of drug efficacy
is based solely on symptoms and walking distance
in the relatively artificial setting of a graded exercise
test on a treadmill.
Cilostazol
Cilostazol (Pletal) is a phosphodiesterase III (PDE III)
inhibitor which is licensed in the USA, Japan and
parts of Europe (UK, Ireland, Germany) for theimprovement of maximal and pain-free walking dis-
tances in patients with IC, in the absence of rest
pain or evidence of peripheral tissue necrosis. The
underlying mechanism of action is not entirely clear,
but weak vasodilator activity, anti-platelet effects
(improving collateral flow) and possibly a direct bio-
chemical action on muscle oxygen consumption and
pain threshold (via increased levels of cyclic AMP)
might all contribute to the improved walking
distances.
A total of 8 multicentre, randomised, placebo-
controlled trials, ranging induration from12e24weeks,
evaluated the efficacy and safety of cilostazol in a total
of 2702 patients with moderate-to-severe IC. Four of
these trials, involving 1534 patients, have been
published,18e21 and two of the trials also included
an active comparator (pentoxifylline).19 The profile of
effect of cilostazol develops over several weeks
(Fig. 1), and a meta-analysis has provided an overview
of the placebo-controlled trials and shown a 40% im-
provement in walking distance, relative to placebo, af-
ter 6 months treatment with cilostazol 100 mg twice
daily (Fig. 2).22 Additional studies and clinical experi-
ence, especially in the USA where cilostazol has been
used extensively for last 8 years, shows significant
benefits in a range of patients with IC,23e26 including
patients with diabetes.27 Table 1 summarises the major
published (placebo-controlled) studies with cilostazol.
It is important to note that the patients enrolled in
the cilostazol trials were typical of the IC population
found in routine clinical practice. For example, they
were mostly elderly (average age was 65 years), 60%
had hypertension and 25% were diabetic. The baseline
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Fig. 1. Effect of cilostazol 100 mg bid (B, n¼ 227) on maxi-
mum (treadmill) walking distance, relative to baseline, com-
pared with placebo (-, n¼ 239) and pentoxifylline 400 mg
tds (:, n¼ 232). *p< 0.05 vs placebo; z p< 0.05 vs pentoxi-
fylline. Adapted from Dawson et al.[20]
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316 T. E. Rowlands and R. DonnellyABPI was 0.64. These patients were also taking a range
of other cardiovascular drugs, e.g anti-hypertensive
and lipid-lowering medications.
Cilostazol is generally well tolerated (Table 2), and
there is now an extensive post-marketing safety data-
base confirming that, unlike other PDEIII inhibitors
(e.g milrinone),28 cilostazol is not associated with ex-
cess cardiovascular deaths.29 Because of safety con-
cerns with milrinone, cilostazol is contra-indicated
in patients with heart failure and/or serious (ventric-
ular) arrhythmias. Cilostazol does not prolong the QTc
interval, and the contra-indication in arrhythmia does
not include patients with lone atrial fibrillation.
The commonest side effect is headache; the
placebo-adjusted incidence was 20% in placebo-
controlled trials. Transient diarrhoea, palpitation and
dizziness (possibly because of cilostazol’s vasodilator
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Fig. 2. A summary of the efficacy data from the 4 published
placebo-controlled trials of cilostazol18e21 for changes in
maximum treadmill walking distance (and 95% confidence
intervals). Adapted from reference 22.effects) also have been recorded in more than 2% of
patients in the 8 placebo-controlled trials (Table 2).22
These effects tend to subside after repeated dosing.
An excess of bleeding episodes may occur with cilos-
tazol, because of its antiplatelet effects, and this is
more likely in patients also taking clopidogrel.29
Cilostazol undergoes extensive hepatic metabolism
by the cytochrome P450 3A4 isoform (CYP3A4) and
therefore drugs which inhibit CYP3A4, e.g cimetidine,
erythromycin, and ketoconazole, will increase plasma
cilostazol concentrations, but in clinical trials and in
routine practice these interactions have not translated
into an increase in cilostazol-related side effects.24
Cilostazol is perhaps the drug with the best evi-
dence in support of its indication in IC. The clinical
trial database involving over 2500 patients in double-
blind, placebo-controlled studies far outweighs any
other research in this field. As well as showing signif-
icant improvements in treadmill walking distance
(which may underestimate the clinical benefit to indi-
vidual patients in routine practice), cilostazol also im-
proved various quality of life (QOL) scores in the
context of double-blind trials. This conclusion is re-
flected in the SIGN guidelines, together with useful
Table 2. Adverse events occurring in more than 2% of patients
during 8 placebo-controlled clinical trials with cilostazol
Side Effect Cilostazol 50 mg
BD (n¼ 303)
Cilostazol 100 mg
BD (n¼ 998)
Placebo
(n¼ 973)
Headache 26% 34% 14%
Palpitation 5% 10% 1%
Tachycardia 4% 4% 1%
Oedema 8% 7% 4%Table 1. Summary of changes in walking distance in each randomised controlled trial of cilostazol in patients with IC
Study Duration of
study
Drug Dose No. of
subjects
Change in maximum
walking distance
(MWD)
Change in pain-free
walking distance
(PFWD)
Change in ankle-
brachial pressure
index (ABPI)
Beebe et al.18 24 weeks Cilostazol 100 mg BD 175 D51% ( p¼ 0.001) D59% ( p< 0.001)
50 mg BD 171 D38% ( p< 0.001) D48% (0.001)
Placebo 170 D15% D20%
Dawson et al.19 12 weeks Cilostazol 100 mg BD 54 D30.5% ( p< 0.01) D31.7% ( p< 0.01)
Placebo 27  9.3%  2.5%
Dawson et al.20 24 weeks Cilostazol 100 mg BD 227 D54% ( p< 0.001) D76% ( p¼ 0.0001) D6%
Pentoxifylline 400 mg TDS 232 D30% ( p¼ 0.82) D60% ( p¼ 0.07) D8%
Placebo 239 D34% D48% 1%
Money et al.21 16 weeks Cilostazol 100 mg BD 119 D40% ( p¼ 0.0001) D9% ( p¼ 0.0125)
Placebo 128 D15% D1%
Strandness et al.25 24 weeks Cilostazol 100 mg BD 124 D64% ( p¼ 0.0003) D73% ( p¼ 0.0015)
50 mg BD 128 D36% D44%
Placebo 125 D18%D D29%
Elam et al.26 12 weeks Cilostazol 100 mg BD 95 D35% ( p¼ 0.004) D9% ( p< 0.001)
Placebo 94 D24.3% D1.2%
Eur J Vasc Endovasc Surg Vol 34, September 2007
317Medical Therapy for Intermittent Claudicationpractical advice to stop cilostazol after 6 months if it is
not clinically benefiting an individual patient and/or
if their symptoms have changed and they no longer
need drug therapy.10
Vascular disease-modifying therapies
As part of secondary prevention to reduce the risk of
major life- or limb-threatening cardiovascular events,
patients with PAD (especially those with IC) are rou-
tinely offered advice about lifestyle changes and
treated with antiplatelet, antihypertensive and lipid-
lowering drugs.7 But to what extent do these interven-
tions affect lower limb symptoms in PAD?
Smoking cessation among patients with IC does not
significantly improve walking distance,6 but it may
reduce the severity of claudication and the risk of
progression to rest pain.30,31 Meta-analyses and
randomised trials have shown that exercise signifi-
cantly improves maximal walking time in patients
with IC. The nature of the exercise should involve reg-
ular walking to near-maximum pain over a period of
at least 6 months. The underlying mechanism by
which exercise improves walking distance is unclear,
but does not seem to work through improved ABPI
or growth of collateral vessels.
Statins have powerful disease-modifying effects
on the atherosclerotic plaque, and there is placebo-
controlled trial evidence showing that simvastatin
and atorvastatin improve treadmill walking distance
in patients with PAD.32,33 Furthermore, some of the
effects of statins on lower limb function and exercise
tolerance may be independent of their cholesterol-
lowering effect.34,35 In the Scandinavian Simvastatin
Survival Study (4S study), only 4% of (4000) patients
had IC at baseline, but the incidence of ‘new or wors-
ening’ IC was significantly lower in patients treated
with simvastatin 40 mg compared with placebo.36
In terms of antihypertensive therapy, beta-
adrenoceptor blockers do not worsen IC [6], but there
is evidence that the combination of atenolol and nifedi-
pinemay reducemaximal treadmillwalkingdistance.37
Angiotensin converting enzyme (ACE) inhibitors, how-
ever, have been shown to improve walking distances.38
Whether these effects are additive to those of cilostazol
is not entirely clear, but in the randomised controlled
trials cilostazol or placebo was added to ‘usual treat-
ments’, which in a large proportion of participants
included ACE inhibitor and/or statin therapy.
Therefore, the recommended medical therapy for
patients with IC depends on whether cilostazol is
licensed and available for local use. The case studies
(1 and 2) show the recommended medical therapyfor a patient with IC according to the availability of
cilostazol.
Case 1: 69y male living in Derby, UK, with stable
IC, type 2 diabetes and a maximum walking
distance of 120 m which is causing significant
life-restriction. His symptoms are bilateral and
troublesome despite optimum BP and lipid con-
trol and use of aspirin 75 mg daily. HbA1c is
8.2% (target HbA1c< 7%). Investigations confirm
diffuse, distal disease that is not amenable to per-
cutaneous or surgical intervention. The patient
does not have heart failure or trophic changes,
and has been trying to exercise regularly for
6 months with only modest improvement.
This patient would be suitable for a therapeutic
trial of cilostazol 100 mg bid, added to current
therapy including exercise. This increases his
maximum walking distance to 200 m, and the pa-
tient reports a significant improvement in symp-
tom severity, exercise tolerance and quality of
life. (If cilostazol is not effective after 6 months,
the drug should be discontinued). The physician
also increases his oral antidiabetic therapy (met-
formin and pioglitazone) to achieve better glycae-
mic control, which in turn is likely to benefit both
micro- and macrovascular disease.
Case 2: A 78y female living in Milan, Italy, under-
went a femoro-popliteal bypass 10 years ago. In
the last 2 years, IC has gradually increased and
her maximum walking distance is now 220 m.
Her past medical history also includes a right ca-
rotid endarterectomy for amaurosis fugax 4 years
ago. She takes very little exercise, and the clinical
assessment shows BP 184/86 mmHg and fasting
LDL-cholesterol 5.7 mmol/L. Serum creatinine
and fasting glucose are normal. Her current
therapies include aspirin 75 mg, dipyridamole
200 mg bid, simvastatin 40 mg, and bendroflume-
thiazide 2.5 mg.
In terms of her medical therapy to improve symp-
toms and cardiovascular outcomes, the focus of
her management should be: (1) regular exercise
to near-maximal pain threshold, ideally 3 or 4
times per week under supervision by an exerciseEur J Vasc Endovasc Surg Vol 34, September 2007
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Cellular Approaches to Augment Growth of New
and Collateral Vessels
The development of collateral vessels is an important
physiological adaptation to chronic ischaemia due to
occlusive arterial disease, and in patients with PAD
the extent of collateralisation can have a major impact
on symptoms, distal blood flow and lower limb out-
comes.39 The regulation of new vessel formation is
complex and incompletely understood, but in normal
tissue turnover and repair there is a fine balance be-
tween pro- and anti-angiogenic pathways. In the con-
text of vascular disease, the duration and severity of
ischaemia, shear stress and activation of local inflam-
matory pathways strongly influence the angiogenic
response.40
Formation of new (collateral) vessels involves at
least 3 distinct biological processes. Angiogenesis is
the sprouting of new capillaries from existing vascu-
lar structures, a process that is triggered by endo-
thelial cell activation, migration and proliferation
followed by remodelling and expansion of the
extracellular matrix.40 Angiogenesis creates a fragile
network of branching points and sprouts new vessels
from arterioles that may lie upstream or downstream
from occluded or tightly stenosed arteries. Vasculo-
genesis, however, is the in-situ formation of new blood
vessels from circulating bone marrow-derived endo-
thelial progenitor cells (EPCs).41 Vasculogenesis oc-
curs in adults (as well as embryos), where EPCs
differentiate into endothelial cells which fuse to
form luminal structures. The process of arteriogenesis
refers to an increase in wall thickness and luminal di-
ameter of existing arteriolar collateral vessels via re-
cruitment of perivascular and smooth muscle cells.
Arteriogenesis develops a smooth muscle layer within
the newly formed vessel in order to withstand arterial
blood pressure. Inflammatory mediators and shear
rehabilitation program; (2) As with many patients,
simvastatin 40 mg is not achieving the recommen-
ded LDL-cholesterol target (<3 mmol/L, ideally
<2 mmol/L). Switching to atorvastatin or rosuvas-
tatin, and/or adding ezetimibe, would be reason-
able options; (3) She has systolic hypertension
and is likely to require at least 2 (probably 3) drugs
to reach the goal of SBP<140 mmHg. Addition of
an ACE inhibitor or angiotensin receptor blocker
would be the preferred option. Surgical manage-
ment would include assessment of the patency of
her fem-pop graft.
Eur J Vasc Endovasc Surg Vol 34, September 2007stress, rather than hypoxia, stimulate arteriogenesis.42
New vessel formation in the myocardium and lower
limbs of patients with PAD is likely to involve a com-
bination of angiogenesis, vasculogenesis and arterio-
genesis (Fig. 3).40e43
Over the last 30 years a number of growth factors
and cytokines have been identified which either stim-
ulate or inhibit angiogenesis.44 In particular, three
groups of growth factors have been targeted by the
biotechnology industry for therapeutic angiogenesis:
(1) the vascular endothelial growth factor (VEGF)
family, which includes VEGF-A, VEGF-B, VEGF-C,
and VEGF-D (post-transcriptional modification of
VEGF-A results in 3 major isoforms: VEGF121,
VEGF165 and VEGF189) (2) the fibroblast growth factor
(FGF) family, e.g. FGF-2 (also known as basic FGF,
bFGF) and FGF-4; and (3) granulocyte monocyte
colony stimulating factor (GM-CSF, which activates
circulating monocytes and stimulates release of bone
marrow derived EPCs).
Therapeutic angiogenesis: proteins or gene transfer?
Therapeutic angiogenesis aims to artificially boost the
natural angiogenic response by increasing substan-
tially the local concentrations of angiogenic growth
factors in the lower limb, either by administering re-
combinant protein or the gene that codes for an angio-
genic growth factor, or by administering EPCs that
will synthesize multiple growth factors near to sites
of new vessel formation.45,46 The strategy for clinical
Fig. 3. Angiogenesis involves endothelial cell activation,
migration and proliferation, followed by expansion and
remodelling of extracellular matrix and smooth muscle
cell recruitment (arteriogenesis) to form luminal structures
capable of maintaining systemic blood pressure. The regula-
tion of angiogenesis is complex, but involves a balance
between pro- and anti-angiogenic growth factors.40e43
319Medical Therapy for Intermittent Claudicationdevelopment has focused mainly on local delivery of
growth factors using gene transfer (delivered by intra-
muscular or arterial catheter).
The principal methods of gene transfer are based on
using either a plasmid (naked DNA) or a viral vector
(e.g. adenoviral or retroviral). Plasmid transfer is
much less efficient (<10% enters the cell nucleus), but
perceived to be safer and can produce increased local
gene expression for up to 4 weeks. Viral-based vectors
provide high rates of gene transfer, but can sometimes
trigger immunological or inflammatory reactions. Ret-
roviral vectors transfer RNA into the target cells, which
is then converted to DNA and incorporated into the
host genome. Theoretically, this should result in indef-
inite overexpression of the transgene.
Randomised controlled trials of recombinant protein or
gene transfer in IC
Following the first case report of VEGF gene transfer
in a patient with critical limb ischaemia,47 there
have been 2 randomised controlled trials in patients
with PAD48,49 to evaluate functional endpoints follow-
ing administration of recombinant protein or gene
transfer (Table 3).
The TRAFFIC study was a double-blind, placebo-
controlled trial of single or repeat-dose intra-arterial
recombinant FGF-2 (rFGF-2). The dose (30 mg/kg)
was the maximum-tolerated dose of rFGF-2 shown
in dose-response tests to avoid inducing systemic hy-
potension. Patients with IC received half the dose of
FGF-2 down each femoral artery via a single arterial
puncture and crossover catheter. Strict inclusion crite-
ria required patients to have two reproducible tread-
mill tests during a 30-day screening period, evidence
of infra-inguinal obstructive arterial disease and a rest-
ing ABPI< 0.8 on the most affected limb. A total of
377 patients were screened to identify 190 who were
eligible for randomisation. Patients were randomised
to placebo, single-dose FGF-2 or two doses of FGF-2
(the second dose given 30 days later). Peak walking
time at 90 days (the primary endpoint) was increased
by 0.6 min with placebo, 1.77min with single-dose
rFGF-2 and by 1.54min with double-dose rFGF-2.By analysis of variance, the difference between groups
was p¼ 0.075, but in a secondary intention-to-treat
analysis (involving all 190 randomised patients) the
difference between groups was p¼ 0.034.48
The Regional Angiogenesis with VEGF (RAVE)
trial used an adenoviral vector to transfer the gene
for VEGF121 (AdVEGF121) in patients with critical
limb ischaemia and reproducible unilateral claud-
ication.49 This was a multicentre, double-blind,
placebo-controlled dose-finding study to assess the
safety and efficacy of intramuscular AdVEGF121 in pa-
tients with unilateral PAD. A total of 105 patients with
exercise-limiting IC on two baseline treadmill tests
(peak walking time between 1 and 10min) were strat-
ified by diabetes status and randomised to low-dose
(4 109 PU) AdVEGF121, high-dose (4 1010 PU) Ad-
VEGF121 or placebo, administered as 20 intramuscular
injections to the index leg in a single session.49 The
primary efficacy endpoint (change in peak walking
time) at 12 weeks was not different between the 3
groups: 1.8 3.2 min (placebo) vs 1.6 1.9 min (low
dose) vs 1.5 3.1 min (high dose). Secondary analy-
ses, including change in peak walking time, ABPI,
claudication onset time and QOL measures (walking
impairment questionnaire) were also similar among
the 3 groups at 12 and 26 weeks.49
Further gene therapy trials in patients with IC are
on-going based on different genes and more sophisti-
cated vectors to achieve higher rates of transfection.
For example, the Del-1 for therapeutic angiogenesis
trial (DELTA-1) is assessing a plasmid-mediated ap-
proach to induce angiogenesis and arteriogenesis us-
ing the angiomatrix protein Del-1 (developmentally
regulated endothelial locus 1).50 VLTS-589 is an inves-
tigational non-viral therapeutic comprising a plasmid
expressing Del-1 formulated with poloxamer 188
(facilitating agent). Over 100 patients with IC will
be randomised in the DELTA-1 trial.
Bone marrow derived EPCs
EPCs are involved in vasculogenesis, and experimen-
tal studies in animal models of PAD have shown that
implantation of bone marrow mononuclear cellsTable 3. Summary of randomised, controlled trials of single or multiple administrations of DNA or recombinant protein to stimulate
angiogenesis in patients with PAD
Treatment Patient group
(No. of subjects)
Route of
Administration
Efficacy Assessment Endpoint (result) Trial Name
Recombinant protein
FGF-2 PAD (n¼ 174) i.a 90 days Peak walking
distance (positive)
TRAFFIC47
Gene therapy
VEGF121 (Adenoviral) PAD (n¼ 105) i.m 12 & 26 weeks Exercise tolerance (negative) RAVE48
Eur J Vasc Endovasc Surg Vol 34, September 2007
320 T. E. Rowlands and R. Donnellypromotes collateral vessel formation with increased
incorporation of EPCs into networks of new vessels.
The TACT study was a randomised controlled trial
of autologous bone marrow derived mononuclear
cells, including EPCs, which were implanted into
critically ischaemic limbs.51 Clinical improvements
(decreased rest pain) were recorded in 39 out of 45
patients, and there were significant increases in
ABPI from 0.35 at baseline to 0.47 after 1 month.51
The attraction of cellular-based therapy is that
EPCs will secrete a range of angiogenic factors to pro-
mote a co-ordinated response leading to new vessel
formation. This strategy, especially in critical ischae-
mia, may be more effective than single protein or
gene transfer techniques.
Conclusions
IC is a common, painful and disabling symptom.
Medical therapy has an important role as an adjunct
to lifestyle modification and (in a small subgroup of
patients) surgical or endovascular procedures. The
focus of treatment is on symptom relief, and second-
ary prevention to reduce the risk of major life- or
limb-threatening cardiovascular complications. There
is good evidence from randomised controlled trials
that cilostazol improves maximum and pain-free
walking distance, as well as QOL, in patients with
IC, although the underlying mechanisms are unclear.
Statins and ACE inhibitors e used extensively for
cardiovascular risk modification and to slow disease
progression and prolong survival in patients with
atherosclerotic disease e also improve exercise toler-
ance in patients with PAD, in part through changes
in vascular structure and function.
In the future, management strategies for PAD will
include treatment modalities that augment new vessel
formation and preserve tissue viability. This will be
especially appropriate for patients with critical limb
ischaemia, rest pain and/or failed revascularisation.
Considerable research is ongoing to refine the instru-
ments for therapeutic angiogenesis based on recombi-
nant proteins and/or gene transfer. In particular,
selecting the right gene or protein, and refining the
mode and route of administration will be key to im-
proving the durability and magnitude of the angio-
genic response.
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